Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Apr 7;11(13):1917-21.
doi: 10.3748/wjg.v11.i13.1917.

Avidin chase reduces side effects of radioimmunotherapy in nude mice bearing human colon carcinoma

Gui-Ping Li  1 , Yong-Xian Wang, Kai Huang, Hui Zhang, Chun-Fu Zhang
Affiliations

Avidin chase reduces side effects of radioimmunotherapy in nude mice bearing human colon carcinoma

Gui-Ping Li et al. World J Gastroenterol. .

Abstract

Aim: To evaluate the influence of avidin chase on the side effects of radioimmunotherapy (RIT) in nude mice bearing human colon carcinoma and therapeutic outcome.

Methods: Purified anti-CEA monoclonal antibody (McAb) was biotinylated with NHS-biotin, and then radiolabeled with 188Re by the direct method. 188Re-labeled biotinylated anti-CEA McAb (188Re-CEA McAb-Bt) was intravenously injected followed by intravenous injection of avidin after 24 h. SPECT imaging and biodistribution study were performed at 28-48 h after the injection of 188Re-CEA McAb-Bt. Three groups of nude mice subcutaneously grafted with human colon carcinoma were treated 7 d after the graft. Mice in the avidin chase group received intravenous injection of 188Re-CEA McAb-Bt (11.1 MBq/20 microg) followed by intravenous injection of cold avidin (80 microg) after 24 h. Mice in the control group (treated group without avidin chase) only received the injection of 188Re-CEA McAb-Bt (11.1 MBq/20 microg), another control group (non-treated group) only received 0.1 mL normal saline solution. Toxicity was evaluated on the basis of change of body weight and peripheral WBC counts, and therapy effects were determined by variation in tumor volume. Histological analysis of tumors was also performed.

Results: Avidin chase markedly accelerated the clearance of 188Re-CEA McAb-Bt from the blood and normal tissues. The tumor uptakes of 188Re-CEA McAb-Bt at 28 h were 5.90 and 6.42% ID/g, respectively, in chase group and in non-chase group, while the tumor-to-background (T/NT) ratios were 3.19 and 0.56, respectively. The tumor uptake was slightly decreased by avidin chase, but the T/NT ratios were increased. In treated groups the growth rate of body weight and the number of WBC decreased after injection of 188Re-CEA McAb-Bt, and the WBC counts recovered earlier in the group with avidin chase than in the group without avidin chase. Compared to the non-treated group, treated groups with and without avidin chase showed significant anti-tumor effects.

Conclusion: Avidin chase can effectively reduce the side effects of RIT, and improve therapeutic efficacy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Tissue radioactivity at 28 and 48 h after administration of 188Re-CEA McAb-Bt in groups without (A) and with Av chase (B).
Figure 2
Figure 2
Tumor-to-non-tumor ratios at 28 and 48 h after administration of 188Re-CEA McAb-Bt in groups without (A) and with Av chase (B).
Figure 3
Figure 3
Radioimmunoimaging in nude mice bearing human colon carcinoma with (A) and without (B) avidin chase at 28 h after administration of 188Re-CEA McAb-Bt.
Figure 4
Figure 4
Change of the number of peripheral blood white blood cells after injection of avidin chase.
Figure 5
Figure 5
Variation of tumor growth volume (cm3) in groups before and after therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bian HJ, Chen ZN, Deng JL. Direct technetium-99m labeling of anti-hepatoma monoclonal antibody fragment: a radioimmunoconjugate for hepatocellular carcinoma imaging. World J Gastroenterol. 2000;6:348–352. - PMC - PubMed
    1. Alvarez-Diez TM, Polihronis J, Reilly RM. Pretargeted tumour imaging with streptavidin immunoconjugates of monoclonal antibody CC49 and 111In-DTPA-biocytin. Nucl Med Biol. 1996;23:459–466. - PubMed
    1. Fritzberg AR. Antibody pretargeted radiotherapy: a new approach and a second chance. J Nucl Med. 1998;39:20N–22N, 36N. - PubMed
    1. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28:1294–1302. - PubMed
    1. Kalofonos HP, Rusckowski M, Siebecker DA, Sivolapenko GB, Snook D, Lavender JP, Epenetos AA, Hnatowich DJ. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med. 1990;31:1791–1796. - PubMed

Publication types